Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

Four young children have gained life-changing improvements in sight following treatment with a pioneering new genetic medicine through UCL Institute of Ophthalmology and Moorfields Eye Hospital, with ...

A revolutionary gene therapy treatment in London has improved the vision of children suffering from a rare genetic disorder, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

The move comes after Commission Chairman Clint Didier invited a group of vaccine skeptics to speak at two recent meetings. It’s the same group behind recent pushes in Idaho to stop offering the ...

The procedure, developed by UCL scientists, consists of injecting healthy copies of the gene into the retina, at the back of ...

The Franklin County Board of Commissioners has passed a resolution urging the Benton Franklin Health District (BFHD) to cease providing, funding, and promoting gene-therapy vaccines until ...